NICE's rejection of crizanlizumab at £733K-1.1M per QALY sets the price ceiling any new UK sickle cell agent must clear, and Casgevy's own access required restructuring £1.65M into an annuity.
The defining UK sickle cell pricing precedent is not a success story. NICE reviewed crizanlizumab under TA743 in 2021 and did not recommend it for routine NHS commissioning, even after Novartis offered a confidential Patient Access Scheme discount. At a UK WAC of roughly £88,000 a year, the modelled cost came to £733,000 to £1.1 million per QALY, far outside NICE's standard threshold, and the drug was withdrawn from the market in 2023 after its confirmatory trial failed. Any new non-gene sickle cell agent inherits that precedent directly: a WAC anywhere near crizanlizumab's is very unlikely to clear NICE, whatever the clinical case. Our price ladder models the WAC range that stays inside NICE's threshold once NHS hospitalisation offsets are built into the case from the outset, not added after a rejection.
Casgevy's own path illustrates the same constraint at gene-therapy scale. Its £1.65 million one-time WAC compares favourably against an estimated £4-6 million NHS lifetime cost of managing a severe SCD patient, but a single lump-sum payment of that size was never going to clear an NHS budget line cleanly. NICE's TA1044 recommendation rests on a managed-access agreement, and NHS England's own modelling frames the economics as a 10-year annuity: roughly £165,000 a year per patient, a marginal improvement over the £80,000-£120,000 a year NHS already spends managing severe SCD conventionally. For a new non-gene agent, the implication is direct: price near £15,000 to £25,000 a year, model the VOC-reduction hospitalisation offset explicitly, and do not anchor to crizanlizumab's WAC.
UK sickle cell pricing — the NICE rejection precedent versus Casgevy's annuity route
| Agent | NICE Outcome | WAC / Cost Mechanism | Cost per QALY |
|---|---|---|---|
| Crizanlizumab (Adakveo) | TA743 not recommended (2021), then withdrawn 2023 | ~£88,000/year, even with confidential PAS | £733,000–1,100,000 |
| Casgevy (exagamglogene autotemcel) | TA1044 recommended with managed access | £1.65M one-time; ~£165,000/year under 10-year annuity | Not disclosed; judged against £4-6M lifetime SCD cost |
| Recommended novel non-gene agent | Target: clears NICE's standard threshold | £15,000–25,000/year | Modelled to clear £20,000-30,000/QALY threshold with hospitalisation offset |
Sources: NICE technology appraisal TA743 (crizanlizumab, final decision); NICE technology appraisal TA1044 (Casgevy, managed access); NHS England SCD gene therapy budget modelling 2024; NHS Hospital Episode Statistics SCD data 2023.
What this model answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The published TA743 cost/QALY calculation (£733K-1.1M)
- the WAC range required to clear NICE's standard £20,000-30,000/QALY threshold
- the hospitalisation-offset argument that closes the gap
Delivers
- The annuity mechanics (£165,000/year)
- the comparison against £80,000-120,000/year current NHS SCD management cost
- NICE's Long-Term Value Framework application
Delivers
- The recommended £15,000-25,000/year target WAC
- per-patient NHS hospitalisation savings modelling
- GTN waterfall and PAS negotiation layers specific to the UK SCD market
Custom model delivered in 72 hours.
Commission This ModelWhat's inside
- Why NICE's crizanlizumab rejection, not clinical need, sets the WAC ceiling any new agent must clear
- Pressure-tested against Casgevy's own annuity restructuring before the rest of the model is built out
- £1.65M one-time WAC decomposed against the £4-6M NHS lifetime management comparator
- Where a novel non-gene agent should sit on the same ladder
- How NHS England's annuity mechanism converts a lump sum into an annual cost
- The marginal cost-effectiveness case versus current SCD management spend
- TA743's cost-effectiveness calculation and why the PAS discount was not enough
- What the rejection means for any agent priced above the implied ceiling
- The WAC range that clears NICE's standard threshold once hospitalisation offsets are modelled
- Positioning against hydroxycarbamide's generic cost floor
- The WAC-to-net waterfall decomposed by NHS commissioning route
- Where a confidential PAS discount does and does not change the NICE outcome
- Sequencing recommendation across NHS England specialist centres
- Conservative, base, and aggressive revenue scenarios tied to NICE submission timing
- The open pricing questions your team must close before the UK launch price is locked
- Structured for an internal pricing committee session
Included with every brief
How AXLRx builds this model
Prepared by MoatRx analysts.
Every AXLRx pricing model is built from primary NICE and NHS sources and live commissioning documentation, not secondary summaries. Findings are independently verified before inclusion.
Sickle cell disease UK pricing sources: NICE TA743 (crizanlizumab), NICE TA1044 (Casgevy), NHS England SCD gene therapy budget modelling 2024, and NHS Hospital Episode Statistics SCD data 2023.
- Crizanlizumab's cost/QALY and NICE rejection verified against the published TA743 decision document
- Casgevy's WAC and annuity modelling verified against NICE TA1044 and NHS England SCD gene therapy budget modelling 2024
- NHS lifetime SCD management cost and hospitalisation-offset figures verified against NHS Hospital Episode Statistics SCD data 2023
Frequently asked questions
Commission this model
AXLRx delivers sickle cell disease pricing strategy models built for market access and pricing teams navigating NICE's cost-effectiveness threshold and the UK annuity payment discussion. Custom model in 72 hours.
Specify your indication, target WAC range, and comparator scope.
AXLRx analyst confirms pricing mechanism assumptions and NICE threshold before building.
Research-verified pricing model in 72 hours with optional analyst readout.